Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs

Clinical Infectious Diseases(2024)10.1093/cid/ciae163Source: DataRank Database

Exploration of a Potential DOOR Endpoint for Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 1.28)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Ursula Waack ORCID,Mark Needles,Daniel B. Rubin ORCID,Deborah Collyar ORCID,Sarah B. Doernberg ORCID

Live enrichment

PubMed:38527855 PMC:PMC11259224 OpenAlex:https://openalex.org/W4394758282

NIAID NIH HHS

Grant: UM1 AI104681

NIH

NIAID

Antibacterial Resistance Leadership Group

Basilea Pharmaceutica

ARLG)

FDA

NIH

ARLG)

FDA

Basilea Pharmaceutica

NIAID

Antibacterial Resistance Leadership Group

FWCI

1.28

Citation Percentile

0.8%

Citation Trend

2025

2026

hybridLicense: public-domain

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae163/57088806/ciae163.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae163/57088806/ciae163.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae163/57439897/ciae163.pdf

publisherhttps://academic.oup.com/cid/article-pdf/79/1/60/58599867/ciae163.pdf

journalhttps://doi.org/10.1093/cid/ciae163

Fields of Study

Nosocomial Infections in ICUSepsis Diagnosis and TreatmentDelphi Technique in ResearchHumansPneumonia, Ventilator-AssociatedAnti-Bacterial AgentsPneumonia, BacterialMaleHealthcare-Associated PneumoniaFemaleUnited StatesClinical Trials as TopicCross InfectionTreatment OutcomeMiddle AgedUnited States Food and Drug AdministrationAged

MeSH Terms

Healthcare-Associated PneumoniaAgedAnti-Bacterial AgentsClinical Trials as TopicCross InfectionFemaleHumansMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationTreatment OutcomePneumonia, BacterialPneumonia, Ventilator-Associated

Keywords

Clinical trialPneumoniaMedicineClinical endpointVentilator-associated pneumoniaIntensive care medicineBacterial pneumoniaAdverse effectRanking (information retrieval)Internal medicineArtificial intelligenceComputer scienceClinical TrialsAntimicrobial TherapyDoorHospital-acquired Bacterial PneumoniaVentilator-associated Bacterial Pneumonia

Sustainable Development Goals

SDG 0: Good health and well-being